Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF)

Last updated: January 23, 2025
Sponsor: Seoul National University Bundang Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Chest Pain

Arrhythmia

Cardiac Disease

Treatment

MEDI-app

conventional treatment

Clinical Study ID

NCT05557123
RIVOX-AF
  • Ages > 19
  • All Genders

Study Summary

RIVOX-AF study is a prospective, multicenter, randomized controlled study in which patients with AF are allocated to medication-app group or conventional treatment group. The App based feed-back algorithm will provide the patients with check taking drug or reminding of taking drug.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with AF aged 19 years or older with one or more comorbidities includingheart failure, myocardial infarction, stable angina, hypertension or diabetesmellitus (Patients can be enrolled 3 months after myocardial infarction orpercutaneous coronary intervention).

  • patients who already took or plan to take rivoxban

  • patients who able to use smart phone

Exclusion

Exclusion Criteria:

  • creatinine clearance <15ml/min

  • moderate or severe mitral stenosis

  • mitral valve operation history

  • current alcohol abuse or alcohol abus history

  • Not eligible for study due to legal or psychiatric problem

  • enrolled other clinical study within 4 weeks

  • declined to enroll the study

Study Design

Total Participants: 1042
Treatment Group(s): 2
Primary Treatment: MEDI-app
Phase:
Study Start date:
March 10, 2022
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • Seoul National University Bundang Hospital

    Seongnam, 13620
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.